Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

An SI Board Since July 1999

Posts	SubjectMarks	Bans	Symbol
250	46	0	DNA

Emcee: esecurities(tm)	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
175	<i>I feel a good dose of vindication on this news.</i> Hold your se	DewDiligence_on_SI	-	12/6/2007
174	Ken, what kind of mistakes? In the fwiw, I've steared people far away from a	zeta1961	-	12/6/2007
173	Thanks. I also made a mistake, it appears. Out. Isn't DNA a Cramer fave?	tom pope	-	12/6/2007
172	You think the stock is a buy at these low prices? I am hearing that they do not	ggamer	-	12/6/2007
171	I was at the meeting. DNA made some significant mistakes with this trial. One	kenhott	-	12/6/2007
170	Merrill (I bought some just after the open, about 50 cents too early): Price Ob	tom pope	-	12/6/2007
169	Merrill: FDA Briefing documents suggest more risk to panel meeting Our assessme	tom pope	-	12/4/2007
168	F.D.A. Criticizes Avastin Use for Breast Cancer [NYT] By ANDREW POLLACK Publish	Doc Bones	-	12/4/2007
167	Genentech Exec Faces Hostile Eye Docs Posted by Jacob Goldstein November 12, 2	Doc Bones	-	11/13/2007
166	Closed ODAC meeting for Avastin in Breast cancer on December 05..hmm, I'm su	zeta1961	-	11/5/2007
165	Genentech's Avastin Helps Profit Rise 21% By THOMAS GRYTA October 16, 2007;	Doc Bones	-	10/16/2007
164	DNA takes preemptive action against Avastin use for AMD: siliconinvestor.com	DewDiligence_on_SI	-	10/11/2007
163	<b>Genentech Getting in Gear</b> online.barrons.com Genentech (DNA	idos	-	9/24/2007
162	ML, first para of write-up: Expecting timely Avastin approval in breast despite	tom pope	-	9/14/2007
161	Threat to Herceptin : ARRAY 380 is initiating a trial in metastatic Breast canc	biotechmoney	-	8/30/2007
160	Can Genentech Stage a Recovery? Biotech Firm's Shares May Languish in Sick	Doc Bones	-	7/23/2007
159	Merrill, pretty blah. Q2 Earnings exceed expectations due to higher Avastin &am	tom pope	-	7/12/2007
158	Cancer and Eye Drugs Lift Genentech's Net By PETER LOFTUS July 12, 2007; [W	Doc Bones	-	7/12/2007
157	I did buy some after hours, to no good effect yet. We'll see how Merrill spi	tom pope	-	7/11/2007
156	>>Genentech Announces Second Quarter 2007 Results Wednesday July 11, 4:03	tuck	-	7/11/2007
155	Merrill Company Updates Genentech Inc (DNA, US$74.34, C-1-9) Weakness is Buying	tom pope	-	6/28/2007
154	Abbott and Genentech Announce Global, Integrated Research, Development and Comme	zeta1961	-	6/26/2007
153	Tpa successful in treating frost-bite. Very preliminary. online.wsj.com	John Metcalf	-	6/19/2007
152	How Genentech Wins At Blockbuster Drugs CEO to Critics of Prices: 'Give Me	Doc Bones	-	6/5/2007
151	All I know is what the blog said: <i>Manegold will be presenting the data	tom pope	-	6/2/2007

Go to reply# or date (mm/dd/yy):